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Abstract
Aims: This prospective, non-randomised, observational study conducted in Europe was designed in order 
to assess the long-term safety and efficacy of the Parachute device in ischaemic heart failure subjects as 
a result of left ventricle remodelling after anterior wall myocardial infarction.
Methods and results: One hundred subjects with New York Heart Association Class II-IV ischaemic 
heart failure (HF), ejection fraction (EF) between 15% and 40%, and dilated akinetic or dyskinetic anterior-
apical wall without the need to be revascularised were enrolled. The primary safety endpoint was proce-
dural- or device-related major adverse cardiac cerebral events (MACCE). The secondary safety endpoint 
was the composite of mortality and morbidity. Secondary efficacy endpoints included haemodynamic meas-
urements determined by echocardiography, LV volume indices, and assessment of functional improvement 
measured by a standardised six-minute walk test. Of the 100 subjects enrolled, device implantation was 
successful in 97 (97%) subjects. The one-year rates of the primary and secondary safety endpoints were 7% 
and 32.3%, respectively. The secondary endpoints, LV volume reduction (p<0.0001) and six-minute walk 
distance improvement (p<0.01), were achieved.
Conclusions: The favourable outcomes observed in this high-risk population provide reassuring safety and 
efficacy data to support adoption of this technology as a therapeutic option for HF subjects. Clinical regis-
tration: www.clinicaltrials.gov numbers are NCT01297296 (PARACHUTE III) and NCT01286116 (cohort 
B subjects).
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One-year outcomes post Parachute device treatment
Introduction
Left ventricle (LV) dilation and remodelling after acute myocar-
dial infarction have been well characterised in experimental and 
clinical investigations1,2. Progressive LV dilation and remodelling 
post myocardial infarction occurred in 33% of subjects enrolled 
in the GISSI-3 trial (n=13,679)3. Symptomatic post-MI LV dila-
tion is more common in subjects with an anterior infarction4. With 
current aggressive invasive strategies and intensive pharmaco-
therapy, acute myocardial infarction (AMI) survival rates have 
increased, but may have created a larger population with greater 
residual myocardial injury and a higher risk of developing heart 
failure (HF)5. Once hospitalised for HF, the overall one-year mor-
tality remains unacceptably high at 32%, in spite of modern phar-
macological and mechanical approaches5. Therapeutic efficacy 
depends, albeit not exclusively, on improvements in LV volumes, 
reduced wall stress and restored geometry, since left ventricular 
end-systolic and end-diastolic volumes are surrogate measures of 
LV remodelling and independent clinical predictors of outcomes 
in HF subjects6.
The concept of percutaneous ventricular restoration (PVR) 
of the LV is based on the premise that a dedicated partitioning, 
compliant device delivered via a catheter-based approach may 
achieve LV volume reduction, geometric reconfiguration, and syn-
chronised wall motion to achieve a more effective ejection while 
minimising the risk of a surgical approach7. Initial studies8,9 in 
subjects with post-MI remodelling and symptoms of New York 
Heart Association (NYHA) Class II-IV HF demonstrated safety, 
feasibility, and favourable LV function as measured by LVESVi, 
LVEDVi, EF and LVEDP. Moreover, improved symptoms and 
functional status were confirmed after 12 months. In these early 
PVR studies, clinical outcomes of mortality, hospitalisations for 
heart failure, and stroke were also improved compared to litera-
ture reports of devices in a similar population10-14 where functional 
outcomes and/or hospitalisation for HF were improved. Three-
year outcome results from the PARACHUTE first-in-human study 




This prospective, non-randomised, observational study conducted 
in 20 medical centres across 10 countries in Europe was designed 
to assess the long-term safety and efficacy of the Parachute device 
(CardioKinetix, Inc., Menlo Park, CA, USA). The study com-
bined enrolment from two contemporaneous studies with con-
secutive enrolment and the same inclusion and exclusion criteria, 
Europe cohort B and PARACHUTE III, which will be collectively 
referred to as PARACHUTE III. Europe cohort A was the first-
in-man cohort enrolled four years prior to cohort B and was not 
included in this analysis for that reason. Following implantation 
of the device, clinical and echocardiographic follow-up was per-
formed at six months and one year (planned annually thereafter up 
to five years).
Figure 1. Illustration of the Parachute device implanted in a dilated 
left ventricle.
SUBJECT SELECTION
The study included subjects with symptomatic ischaemic HF of 
NYHA Class III, IV, or Class II if diagnosed with NYHA Class 
III or IV during a three-month period prior to enrolment. The sub-
jects were at least 18 years of age with LV wall motion abnormali-
ties (anteroapical akinesis or dyskinesis) secondary to MI, an LV 
ejection fraction between 15% and 40%, and managed with stable 
doses of standard HF medical therapy for at least three months, as 
determined by the investigator. Subjects with myocardial ischae-
mia who underwent revascularisation or cardiac resynchronisation 
therapy within 60 days of enrolment and those with significant 
valve disease were excluded from the study. All sites obtained 
approval from an ethics committee before study commencement, 
and written informed consent was obtained for all subjects at the 
appropriate time prior to involvement in the study.
STUDY DEVICE AND PROCEDURE
The Parachute system includes the device (Figure 1), a delivery 
system with a balloon that facilitates expansion of the device, and 
a pre-shaped delivery catheter and dilator. The Parachute device 
comprises a self-expanding nitinol frame, an ePTFE impermea-
ble membrane, and an atraumatic polymer foot, which has eight 
sizes (65, 75, 85 and 95 mm diameter, each offered in two “foot” 
heights). The distal atraumatic foot is radiopaque and provides 
a contact point between the LV apical wall. The contact point is 
selected in order to orient the device with a vector towards the 
outflow tract.
The procedure is illustrated in Figure 2 and is performed in 
a catheterisation laboratory with the subjects usually under con-
scious sedation15. Subjects were considered intention-to-treat if 
i) they signed a consent form, ii) they underwent a baseline evalu-
ation, and iii) the Parachute procedure was attempted by passage 
of the implant past the guide catheter. Device size selection was 
based on multislice computed tomography which also allowed 
identification of any LV apical thrombus, pseudo-chordae, or 






















All subjects received low-dose aspirin and anticoagulation with 
warfarin for at least 12 months post device implant.
DATA COLLECTION AND OVERSIGHT
All study-related data were collected on standardised electronic 
case report forms. All study-mandated echocardiograms were sent 
to an independent core laboratory (Yale Cardiovascular Research 
Group, Yale University School of Medicine, New Haven, CT, 
USA). Data management was performed by an independent con-
tract research organisation. An independent clinical events com-
mittee (CEC) adjudicated serious adverse events (SAEs), cardiac 
and non-cardiac mortality, and hospitalisations for HF related to 
either device or procedure.
STUDY ENDPOINTS
The primary endpoint of the PARACHUTE III study was the 
assessment of long-term safety as measured by procedural- or 
device-related major adverse cardiac cerebral events (MACCE) 
in real-world use of the Parachute device up to five years post 
procedure; one-year safety data are reported here. MACCE was 
broadly defined and included the occurrence of any of the follow-
ing: death, cardiac death, MI, emergent cardiac surgery, erosion of 
the device through the LV, cardiac tamponade, peripheral embo-
lisation (including stroke), new or worsening HF, endocarditis or 
device infection, device migration or embolisation, or placement 
of a mechanical support device. Worsening HF was defined as an 
unplanned hospitalisation that resulted in at least one overnight 
stay (i.e., where the admission date and the discharge date were 
different) that included increased signs and/or symptoms of wors-
ening HF including increased jugular venous pressure (JVP) and 
required the administration or augmentation of intravenous HF 
therapy (e.g., inotropes, diuretics, and/or vasodilators). Vascular 
complications were defined using an expanded Valve Academic 
Research Consortium (VARC) definition which even included 
damage of the aortic valve requiring surgery16. The secondary 
safety endpoint was the composite of mortality and morbidity. 
Secondary efficacy endpoints included haemodynamic measure-
ments determined by echocardiography, LV volume indices, and 
assessment of functional improvement measured by a standardised 
six-minute walk test (6MWT). A clinically meaningful change in 
the six-minute walk test was defined as an absolute change of 
20 metres.
Figure 2. Sequence of a Parachute implantation in the left ventricle 
(LV). A) Pigtail in the LV cavity to perform LV angiography. 
B) Device placement with foot exposed and in contact with the 
antero-apical wall. C) Balloon inflation to facilitate self-expansion of 
the device. D) Device fully expanded but still attached to the delivery 
system. E) Final positioning after release of the device.
Statistical analysis
The primary endpoint and secondary safety endpoint analysis 
will be performed on the intention-to-treat population. Separate 
analysis for the effectiveness endpoints will be performed on the 
as-treated population. Baseline characteristics were summarised 
using mean±SD for continuous variables and counts and percent-
ages for categorical variables. All statistical comparisons were 
two-sided t-tests or paired t-tests with alpha=0.05. MACCE over 
time was evaluated using Kaplan-Meier analysis. All analyses 
were performed using SAS version 9.3 (SAS, Cary, NC, USA).
Results
SUBJECT POPULATION
Between June 2011 and May 2013, 100 subjects (Online Appendix, 
Table 1) were enrolled into the study. Of the 100 subjects, 55 came 
from the Europe cohort B study and 45 from the PARACHUTE III 
study. The protocol inclusion and exclusion criteria were the same 
for both studies and all subjects selected from both studies are 
included. Ninety-seven subjects were treated with the Parachute 
device and followed up for haemodynamic, functional, and clini-
cal outcomes. The disposition of subjects who completed one-year 
follow-up is shown in Figure 3.
BASELINE CHARACTERISTICS
While all of the subjects were required to have had a diagnosis 
of NYHA Class III or IV during the three-month period prior 
to enrolment to be included in the study, 56% were Class III 
and 44% were Class II at the time of their baseline assessment. 
Ischaemic heart disease was present in all subjects, and approx-
imately one third had been hospitalised for HF in the previous 
12 months. Most subjects were male (81%), and 85% had a prior 
percutaneous coronary intervention (PCI). Nearly all subjects were 
on a beta-blocker (97%), with 79% taking a beta-blocker, diuretic, 
and an ACE or ARB.
100 ITT subjects
97 treated subjects
92 at 6 mo FU







Figure 3. Disposition of intention-to-treat subjects. The three 
unsuccessful cases were due to non-optimal positioning of a device 
resulting in a snared removal (1), and LV perforation by the guide 






















One-year outcomes post Parachute device treatment
PROCEDURAL OUTCOMES AND COMPLICATIONS
Of the 100 intention-to-treat subjects, the procedural success rate 
was 97% (Table 2). In three subjects the device was explanted 
prior to discharge: one for non-optimal positioning of a device 
resulting in a snared removal and two for LV perforation by the 
guide catheter, requiring surgery. Major vascular complications 
were noted in 11% (11/100) of subjects, consisting of four life-
threatening or disabling bleeding events due to an overt source 
Table 1. Baseline characteristics.
Device success 97% (97/100)
Age, years 62.8±10.4




Ischaemic heart failure 100% (100/100)
NYHA II* 44% (44/100)
NYHA III 56% (56/100)
6-minute walk test, metres 353.6±111.6
Smoking history 74% (74/100)
History of stroke 7% (7/100)
History of hypertension 72% (72/100)
History of diabetes 38% (38/100)
History of dyslipidaemia 84% (84/100)
Prior ICD implantation 41% (41/100)
Prior CRT device 9% (9/100)
Prior PCI 85% (85/100)
Prior CABG surgery 13% (13/100)
HF hospitalisation 12 mo before enrolment 30% (30/100)
Data are presented as either percent or mean±SD for subjects where 
treatment was attempted. * NYHA III or IV in the last three months. 
CABG: coronary artery bypass grafting; CRT: cardiac resynchronisation 
therapy; HF: heart failure; ICD: implantable cardioverter-defibrillator; 
PCI: percutaneous coronary intervention
Table 2. Procedural data.
n/N (%)
Treatment success 97/100 (97)
LV perforation 2
Positioning/Snare removal 1
Device size 65 mm 5/100 (5)
75 mm 37/100 (37)
85 mm 35/100 (35)
95 mm 23/100 (23)
Mean±SD
Duration, min 94.1±43.8
Fluoroscopy time, min 23.3±32.1 
Days in hospital prior to discharge 6.1±3.2
SD: standard deviation
of bleeding requiring more than four units of blood, three aortic 
valves requiring surgical repair, two LV perforations preventing 
successful implantations, one bradycardia due to AV block prior 
to the Parachute deployment that was considered life-threatening, 
and one case of mitral apparatus damage. Minor vascular com-
plications were infrequent, related to the femoral access site, and 
were noted in 4% (4/100) of subjects.
MEDICAL THERAPY
The medical therapy was consistent from inclusion into the trial up 
to one-year follow-up for the subjects. The proportion of subjects 
on the following medication at baseline and one-year follow-up, 
respectively, was ACEi 68% versus 69%, ARB 25% versus 24%, 
beta-blockers 97% versus 94%, diuretics 86% versus 91%, and 
anti-arrhythmic 18% versus 17%. The changes in proportions of 
medications taken were not statistically significant. The proportion 
of subjects taking a beta-blocker, diuretic, and an ACE or ARB at 
one year remained unchanged as compared to baseline.
LONG-TERM SAFETY OUTCOMES (MACCE)
The primary safety endpoint (MACCE) at one year was 7.0% and 
was used to assess the long-term safety as measured by proce-
dural- or device-related MACCE (Table 3, Figure 4). All seven 
of the events occurred no later than 10 days after the procedure. 
There was a total of 93 (93%) subjects without a device-related 
major adverse cardiac or cerebral event. The most frequently 
reported MACCE was emergent cardiac surgery. There were no 
device dislodgements or pericardial effusions requiring clinical 
intervention caused by the device. Additionally, as assessed by the 
echo core lab, 3.3% of subjects had thrombus on the device at one 
year all of which were without peripheral embolisation.
HAEMODYNAMICS AND FUNCTIONAL OUTCOMES
The secondary endpoints, LV volume reduction (p<0.0001) and 
six-minute walk distance improvement (p<0.01), were achieved 
Table 3. Hierarchical procedure- or device-related major adverse 





Emergent cardiac surgery 3 (3)
Erosion of device through LV 0 (0)
Cardiac tamponade 0 (0)
Peripheral embolisation/stroke 1 (1)
New or worsening HF 1 (1)
Endocarditis or device infection 0 (0)
Device migration 1 (1)
Device embolisation 0 (0)






















with statistical significance. Improvement of systolic cardiac func-
tion was noted in LV volume indices and contractility index, along 
with trends in ejection fraction and stroke work index, at one-year 
follow-up relative to baseline values. This was accompanied by 
a significant reduction (p=0.05) in left atrial volume (Table 4).
Moreover, the mean NYHA class of subjects (2.0±0.7) was sig-
nificantly reduced after one year (p<0.001) from baseline NYHA 
class (2.6±0.5), reflecting functional improvement. The propor-
tion of subjects who improved at least one NYHA class was 43%, 
while 37% had no change in their NYHA class (Table 5).
Performance on 6MWT was also improved from 372 metres at 
baseline to 397 at 12 months (p<0.01) (Table 5), with 46% of sub-
jects improving by 20 metres or more compared to baseline.
CLINICAL OUTCOMES
The composite secondary endpoint rate of mortality and morbid-
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Figure 4. Primary endpoint Kaplan-Meier plot.
Table 4. Haemodynamic outcomes for Parachute-treated subjects at 12 months.
N Baseline 12 months p-value
Heart rate, beats per min 83 69.0±13.7 69.1±10.7 0.90
Blood pressure Systolic, mmHg 82 120.5±16.3 118.3±13.8 0.22
Diastolic, mmHg 82 72.5±10.1 71.9±9.5 0.63
Left ventricular volume ESVi*, mL/m2 64 84.0±24.2 70.5±24.5 <0.0001
EDVi*, mL/m2 64 117.3±26.3 99.1±27.3 <0.0001
Systolic function Ejection fraction, % 64 29.2±7.9 31.0±7.6 0.10
Fractional shortening, % 57 18.6±9.7 20.1±8.5 0.32
Contractility index, mmHg-m2/mL 63 1.4±0.5 1.7±0.6 <0.001
Stroke work/EDVi, mmHg 63 27.7±9.7 29.8±7.8 0.12
Diastolic function LAVi, mL/m2 50 42.5±15.8 38.3±11.2 0.05
*The functional LV volume is used in the follow-up echo variables. The functional volume is defined as total LV volume less the partitioned volume by 
the Parachute device. EDVi: end-diastolic volume index (mL/m2); ESVi: end-systolic volume index (mL/m2); LAVi: left atrial volume index
Table 5. Functional outcomes.
Baseline 12 months p-value
NYHA class*, mean±SD 2.6±0.5 2.0±0.7 <0.001
NYHA class, 
n (%)
I 0 19 (19.6)
II 43 (44.3) 45 (46.4)
III 54 (55.6) 18 (18.6)
IV 0 0
Missing data 0 15 (15.5)
6MWT**, metres 372 397 <0.01
*N=97 for the treated population. **N=76. NYHA: New York Heart 
Association; 6MWT: six-minute walk test
Table 6. Percentages of subjects experiencing one of more 
clinical outcomes over 12 months.
12 months
n=97
Mortality, % (n) 9.5% (9)
Cardiac mortality 8.4% (8)
Mortality+heart failure hospitalisations 26.0% (25)
Heart failure hospitalisations 24.1% (23)
Myocardial infarction 6.4% (6)
Stroke 3.2% (3)
for HF (12), myocardial infarction (9), and stroke (3) (Table 6, 
Figure 5). The average time to first event was 113±98 days. The 
more contemporary endpoints utilised in HF trials of mortality and 
the combination of mortality and HF hospitalisation had one-year 
results of 9.5% and 26.0%, respectively.
Discussion
The PARACHUTE III study confirms the safety of PVR ther-
apy to treat subjects with ischaemic HF and akinetic or dyskinetic 
anterior-apical wall. The outcomes observed in subjects treated 
with the Parachute device demonstrated the safety and efficacy 
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Figure 5. Secondary endpoint (mortality and morbidity) Kaplan-
Meier plot.
previously reported results15. These results showed a significant 
reduction of left ventricle and left atrial volumes for up to one 
year post implant, and concomitant improvements in HF symp-
toms. Most notable from a subject perspective is that nearly half 
demonstrated clinically significant improvement in the 6MWT. It 
has been well documented that functional capacity of HF subjects 
declines over time6. Against this declining profile of HF subjects, 
approximately 75-80% of the Parachute population is improving 
(approximately 50%) or maintaining (approximately 30%) func-
tional status at one year.
Product development efforts have been implemented to address 
the potential for aortic valve damage during initial crossing into 
the LV. The design change is to taper the dilator to create a smooth 
transition from the guide catheter down to a 0.035” wire.
A recent meta-analysis using mortality data from 30 trials with 
a median follow-up of 17 months highlighted the critical role of 
LV end-systolic and end-diastolic volume reduction for the success 
of pharmacological and mechanical approaches to HF17. A curve 
from this publication correlates the amount of end-systolic vol-
ume (ESV) reduction with the predicted probability of showing 
a reduction in mortality. A 25 mL reduction of ESV corresponds 
to a predicted probability of a mortality reduction of more than 
80%. The ESV as reduced by the Parachute device was sustained 
for one year, ranging between 30 mL and 40 mL. The Parachute 
data reported must be interpreted with caution as the compiled 
data did not include mechanical or direct reduction of LV volume. 
Nevertheless, the current low mortality rate of 9.5% in this pop-
ulation does hold promise that mechanically reducing ESV can 
impact on mortality rates in an HF population.
The unique Parachute mechanism of action combines the con-
cepts and principles from the surgical ventricle restoration proce-
dure popularised by Dor, Menicanti, and Suma18 and distinctive 
features of a mechanical device made of nitinol to be delivered 
percutaneously under fluoroscopy. The Parachute device is the first 
device designed specifically for PVR to treat subjects with ischae-
mic cardiomyopathy akinetic/dyskinetic anterior wall motion and 
HF symptoms. The device shape was designed to partition the 
damaged, non-contractile myocardium while creating a new apex 
and restoring the elliptical shape of the LV cavity in a reproduci-
ble manner. The device also permits contraction of any underlying 
healthy myocardium. The percutaneous nature of the procedure, 
which is performed under local anaesthesia, minimises opera-
tive risk and avoids suture-related myocardial scar. There are sev-
eral possible mechanisms by which the implant of the Parachute 
device may improve cardiac performance and explain these initial 
positive results. The first is that reduction of volumes and parti-
tion of non-viable myocardium may reduce contractile wall stress. 
The second is that the shape of the device and its nitinol fram-
ing may help to restore the elliptical shape of the LV cavity and 
allow systolic torsion, respectively. The third is the substitution of 
the scarred, eccentric anteroapical wall motion with a compliant 
device that promotes synchronised contraction and actively aids in 
diastolic relaxation with outward radial force using stored kinetic 
energy, much like a trampoline19. The benefits of synchronised 
apical wall motion throughout the cardiac cycle allow improved 
cardiac output and reduced filling pressure.
In order to match the six-month cardiac function of a Parachute 
subject with a computational model, the material properties of 
the model had to be adjusted20. The principal finding was that the 
six-month model was associated with a decrease in LV diastolic 
stiffness and a large reduction in myofibre stress at end diastole. 
Another element supporting the fact that the Parachute affects 
diastolic compliance is the demonstration of remodelling of the 
left atrium, which is a surrogate measure for reducing left ventri-
cle end-diastolic filling pressure. Cardiac resynchronisation ther-
apy (CRT) is the only other medical device for HF subjects that 
has shown left atrial remodelling21.
In comparison to other structural heart and HF devices, the 
vascular complications are less than those observed in transcath-
eter aortic valve replacement (TAVR) which uses a similar access 
method, while the haemodynamic and functional improvements 
are similar to those observed in CRT10,21,22. The ongoing US piv-
otal trial, PARACHUTE IV, will enrol 560 subjects and will com-
plement the level of evidence for this technology since it will be 
the first trial randomising against all appropriate medical therapy 
(AAMT) according to the current ACC/AHA guideline update for 
the diagnosis and management of chronic heart failure23.
Limitations
The study does have limitations given its unblinded, single-arm 
nature. Because of this study design, one cannot rule out potential 
bias in the adjudication process, and without a control group con-
clusions should be made with caution. The vascular access bleed-
ing events were adjudicated using the original VARC definitions 























The favourable outcomes observed in this high-risk population 
provide reassuring safety and efficacy data to support adoption of 
this technology as a therapeutic option for heart failure subjects. 
The ongoing large-scale, randomised clinical trial in the USA will 
potentially validate the present results and establish the role of this 
novel therapeutic approach for subjects with ischaemic HF.
Impact on daily practice
The number of subjects with HF continues to grow every year 
with limited therapeutic options. This report provides data on 
the potential of a novel technology, the Parachute device, to 
improve outcomes among select subjects with post-myocardial 
infarction heart failure. The favourable outcomes observed in 
this high-risk population provide reassuring safety and efficacy 
data to support adoption of this technology as a therapeutic 
option for HF subjects.
Appendix
Enrolling centres: University of Rostock, Germany (14); Pauls 
Stradins Clinical University Hospital, Latvia (13); Clinical Center 
of Serbia, Serbia (10); Asklepios Klinik St. Georg, Germany 
(8); Hospital Santa Marta, Portugal (8); Ferrarotto University 
Hospital Catania, Italy (7); University of Heidelberg, Germany 
(6); Antwerp Cardiovascular Institute Middelheim, Belgium (5); 
Centro Hospitalar de Vila Nova de Gaia, Portugal (5); Kerckhoff 
Clinic, Germany (4); St. Thomas’ Hospital, United Kingdom 
(4); OLV Hospital Aalst, Belgium (3); Arzt St. Marien-Hospital, 
Germany (2); Hospital Clinico de Barcelona, Spain (2); Papworth 
Hospital NHS, United Kingdom (2); Golden Jubilee Hospital, 
United Kingdom (2); University Clinic Center Ljubljana, Slovenia 
(2); University College London The Heart Hospital, United 
Kingdom (1); University of Amsterdam Academic Medical 
Center, The Netherlands (1); University Medical Center Utrecht, 
The Netherlands (1).
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